Recombinant mouse antibody to gp41. T26 was found to predominantly bind to oligomeric gp41 and not to monomeric gp41. Binding of this Ab to H9/IIIB-infected cells gave a weak signal which was slightly increased by sCD4 pretreatment.
Figure 1 WB analysis of mAbs. Each WB strip was incubated with 20 µl sera, 32 µg T26 mAb or 4 µg other mAbs diluted with 2 ml wash solution.
The
healthy volunteer sera as negative control and AIDS patient sera as positive
control reference were performed.
Guenaga, J., Dosenovic, P., Ofek, G., Baker, D., Schief, W. R., Kwong, P. D., ... & Wyatt, R. T. (2011). Heterologous Epitope-Scaffold Prime∶ Boosting Immuno-Focuses B Cell Responses to the HIV-1 gp41 2F5 Neutralization Determinant. PloS one, 6(1).
Figure 2 Properties of mAbs binding to H9/IIIB or MN. Effect of sCD4 to env protein on H9/IIIB.
Each bar ( ± S.E.M.) presents the
mean of triplicate determinations.
Usami, O., Xiao, P., Ling, H., Liu, Y., Nakasone, T., & Hattori, T. (2005). Properties of anti-gp41 core structure antibodies, which compete with sera of HIV-1-infected patients. Microbes and infection, 7(4), 650-657.
Figure 3 Inhibition of sera against binding of mAbs 50.69, 98.6, T26 and 902.
The average of competition between pre-bound sera and mAbs.
Usami, O., Xiao, P., Ling, H., Liu, Y., Nakasone, T., & Hattori, T. (2005). Properties of anti-gp41 core structure antibodies, which compete with sera of HIV-1-infected patients. Microbes and infection, 7(4), 650-657.
Figure 4 The temperature dependency of MAb T26 binding.
MAb T26 binding to H9/IIIB at 37 C was higher than at 4 C.
Usami, O., Xiao, P., Ling, H., & Hattori, T. (2006). Competitive Study of Monoclonal Antibodies against the HIV‐1 Gp41 Core Structure. Microbiology and immunology, 50(2), 131-134.
Figure 5 The decreased binding of biotinylated MAb 50.69, 98.6, or T26 to H9/IIIB cells after preincubation with MAb 50.69 (open bars), 98.6 (filled bars), or hIgG (gray bars).
The negative control was calculated as the MFI without preincubation MAb and with biotinylated MAb.
Usami, O., Xiao, P., Ling, H., & Hattori, T. (2006). Competitive Study of Monoclonal Antibodies against the HIV‐1 Gp41 Core Structure. Microbiology and immunology, 50(2), 131-134.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MHH-486 | Recombinant Human Anti-HIV-1 gp41 Antibody | ELISA, IP, FuncS | IgG |
MRO-842CQ | Mouse Anti-HIV-1 gp41 Recombinant Antibody (clone 1911) | WB | Mouse IgG2a |
MRO-843CQ | Mouse Anti-HIV-1 gp41 Recombinant Antibody (clone 191) | WB | Mouse IgG2 |
MRO-844CQ | Mouse Anti-HIV-1 gp41 Recombinant Antibody (clone 10E9) | WB, RIPA, ELISA, IF | Mouse IgG1 |
MRO-845CQ | Mouse Anti-HIV-1 gp41 Recombinant Antibody (clone 10F6) | ELISA, WB, IP, IF | Mouse IgG2b |
There are currently no Customer reviews or questions for MRO-4181CQ. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.